Source-grounded facts extracted from TENAX THERAPEUTICS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
TENAX THERAPEUTICS, INC. shareholders approved Ratification of Appointment of Cherry Bekaert LLP as Independent Registered Public Accounting Firm at the 2026-06-02 meeting.
“The Company’s stockholders ratified the appointment of Cherry Bekaert LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 by the votes indicated below.”
TENAX THERAPEUTICS, INC. shareholders approved Election of Directors at the 2026-06-02 meeting.
“The Company’s stockholders elected each of the following individuals to the Company’s Board of Directors for a one-year term expiring in 2027, or until his or her successor is duly elected and qualified, by the votes indicated below.”
TENAX THERAPEUTICS, INC. reported the quarter ended March 31, 2026 results: net income $15.7 million.
“Tenax Therapeutics reported a net loss of $15.7 million for the first quarter of 2026, compared to a net loss of $10.4 million for the first quarter of 2025.”
TENAX THERAPEUTICS, INC. reported year ended December 31, 2025 results: net income net loss of $52.6 million.
“Tenax Therapeutics reported a net loss of $52.6 million for the year ended December 31, 2025, compared to a net loss of $17.6 million for the year ended December 31, 2024.”
TENAX THERAPEUTICS, INC. reported fourth quarter ended December 31, 2025 results: net income net loss of $15.5 million.
“Tenax Therapeutics reported a net loss of $15.5 million for the fourth quarter of 2025, compared to a net loss of $6.3 million for the fourth quarter of 2024.”
TENAX THERAPEUTICS, INC.: Amendment to Certificate of Incorporation to add provisions exculpating certain officers from liability in specific circumstances (effective 2025-06-13).
“On June 11, 2025, Tenax Therapeutics, Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, upon the recommendation of the Company’s Board of Directors (the “Board”), the Company’s stockholders approved the Certificate of Amendment (the “Officer Exculpation Amendment”) to the Company’s Certificate of Incorporation, as amended (the “Certificate”) to add provisions to the Certificate exculpating certain officers of the Company from liability in specific circumstances, as permitted by Delaware law.”
TENAX THERAPEUTICS, INC. reported first quarter ended March 31, 2024 results: net income $3.8 million.
“Tenax Therapeutics reported a net loss for the first quarter of 2024 of $3.8 million”
TENAX THERAPEUTICS, INC. reported year ended December 31, 2023 results: net income $7.7 million.
“Tenax Therapeutics reported a net loss for 2023 of $7.7 million”
TENAX THERAPEUTICS, INC. amended Amendment with Orion Corporation (effective 2024-02-19).
“On February 19, 2024, Tenax Therapeutics, Inc. (the “Company”) and Orion Corporation (“Orion”) entered into an amendment (the “Amendment”) to that certain License Agreement between the Company and Orion dated as of September 20, 2013, as previously amended on October 9, 2020 and January 25, 2022 (the “Agreement”).”
TENAX THERAPEUTICS, INC. entered into Warrant Agency Agreement with Direct Transfer LLC (effective 2024-02-12).
“On February 12, 2024, the Company also entered into a warrant agency agreement (the “Warrant Agency Agreement”) with the Company’s transfer agent, Direct Transfer LLC, who will act as warrant agent for the Company, setting forth the terms and conditions of the Common Warrants.”
TENAX THERAPEUTICS, INC. entered into Purchase Agreement with certain purchasers valued at gross proceeds of approximately $9.0 million (effective 2024-02-08).
“On February 8, 2024, Tenax Therapeutics, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with certain purchasers”
TENAX THERAPEUTICS, INC. entered into Placement Agency Agreement with Roth Capital Partners, LLC valued at gross proceeds of approximately $9.0 million (effective 2024-02-08).
“On February 8, 2024, Tenax Therapeutics, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”)”
TENAX THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding other (rules 5550(a)(4)).
“January 11, 2024, Tenax Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) regarding compliance with Nasdaq Listing Rule 5550(a)(4) (the “Rule”) which requires the Company to have a minimum of 500,000 publicly held shares. The letter from Nasdaq indicated that according to its calculations, as of January 3, 2024, the day after the Company effected a 1-for-80 reverse split of its common stock, the Company no longer meets the requirements of the Rule. This notice of noncompliance has no immediate impact on the cont”
Lawrence R. Hoffman was appointed as Interim Chief Financial Officer at TENAX THERAPEUTICS, INC..
“On January 9, 2024, the Company’s Board of Directors (the “Board”) appointed Lawrence R. Hoffman as Interim Chief Financial Officer of the Company effective January 11, 2024”
Eliot M. Lurier departed as Chief Financial Officer at TENAX THERAPEUTICS, INC..
“Mr. Hoffman succeeds Eliot M. Lurier, who passed away in December 2023”
TENAX THERAPEUTICS, INC.: Effected a 1-for-80 reverse stock split of common stock via Certificate of Amendment to Certificate of Incorporation (effective 2024-01-02).
“Tenax Therapeutics, Inc. (the "Company") filed a Certificate of Amendment to the Company’s Certificate of Incorporation, as amended (the “Certificate of Amendment”) with the Secretary of State of Delaware for the purpose of effecting a reverse stock split of the outstanding shares of the Company’s common stock at a ratio of one share for every 80 shares outstanding (the “Reverse Stock Split”), so that every 80 outstanding shares of common stock before the Reverse Stock Split represents one share of common stock after the Reverse Stock Split.”
TENAX THERAPEUTICS, INC. shareholders approved Adjournment of Special Meeting to permit further solicitation and vote of proxies at the 2023-11-30 meeting.
“The Adjournment Proposal was approved at the Special Meeting, with a vote of 6,308,531 shares for, 5,052,193 shares against, 225,425 shares abstaining, and no broker non-votes.”
TENAX THERAPEUTICS, INC. shareholders approved Approve amendment to certificate of incorporation to authorize a reverse stock split at the 2023-11-30 meeting.
“The vote for this proposal was 6,198,812 shares for, 5,364,151 shares against, 23,186 shares abstaining, and no broker non-votes.”
TENAX THERAPEUTICS, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“September 28, 2023, Tenax Therapeutics, Inc. (the “Company”) received formal notice that the Nasdaq Stock Market LLC (“Nasdaq”) granted the Company’s request for an extension through March 25, 2024 (the “Extension Notice”) to evidence compliance with the $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). If at any time before March 25, 2024, the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of ten consecutive business days, Nasdaq will provide the Company w”
TENAX THERAPEUTICS, INC.: Amended and restated bylaws effective August 9, 2023, including changes to quorum for stockholder meetings, adjournment mechanics, and director removal provisions (effective 2023-08-09).
“On August 9, 2023, the Board of Directors of Tenax Therapeutics, Inc. (the “Company”) approved the Company’s Fourth Amended and Restated Bylaws, effective immediately upon approval by the Board (the “Amended and Restated Bylaws”). The amendments enacted by the Amended and Restated Bylaws, among other things: (i) amend Article II, Section 9 regarding quorum for stockholders meetings to allow for quorum to be obtained through the presence in person or by proxy of the holders of one-third of the shares entitled to vote, (ii) add a provision clarifying the mechanics to adjourn stockholder meetings, (iii) provide for the removal of directors with or without cause by majority vote of the stockholders, and (iv) include certain other ministerial, clarifying and conforming changes.”
TENAX THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“March 29, 2023, Nasdaq Stock Market LLC (“Nasdaq”) notified Tenax Therapeutics, Inc. (the “Company”) that for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until September 25, 2023, to regain compliance with the Bid Price Rule. If at any time before September 25, 2023”
TENAX THERAPEUTICS, INC. terminated Lease with CCP Concourse, LLC valued at $169,867.41 (effective 2023-02-08).
“On February 7, 2023, Tenax Therapeutics, Inc. (the “Company”) entered into a Lease Termination Agreement with CCP Concourse, LLC, a Virginia limited liability company (the “Landlord”) with respect to the Company’s lease (the “Lease”) of its headquarters formerly located at ONE Copley Parkway, Suite 490, Morrisville, North Carolina (the “Premises”).”
TENAX THERAPEUTICS, INC. entered into Securities Purchase Agreement with certain purchasers valued at Gross proceeds of approximately $15.6 million (effective 2023-02-03).
“On February 3, 2023, Tenax Therapeutics, Inc. (the “Company”) entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with certain purchasers for the purchase and sale, in a registered public offering by the Company (the “Public Offering”), of (i) an aggregate of 6,959,444 shares of its common stock, par value $0.0001 per share (“Common Stock”) and pre-funded warrants to purchase an aggregate of 1,707,222 shares of Common Stock (the “Pre-Funded Warrants”) and (ii) accompanying warrants to purchase up to an aggregate of 17,333,332 shares of its Common Stock (the “Common Warrants”) at a combined offering price of $1.80 per share of Common Stock and associated Common Warrant, or $1.799 per Pre-Funded Warrant and associated Common Warrant, resulting in gross proceeds of approximately $15.6 million.”
TENAX THERAPEUTICS, INC. entered into Placement Agency Agreement with Roth Capital Partners, LLC valued at Cash fee of 7% of aggregate gross proceeds raised in the Public Offering (effective 2023-02-03).
“(the “Company”) entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with certain purchasers for the purchase and sale, in a registered public offering by the Company (the “Public Offering”), of (i) an aggregate of 6,959,444 shares of its common stock, par value $0.0001 per share (“Common Stock”) and pre-funded warrants to purchase an aggregate of 1,707,222 shares of Common Stock (the “Pre-Funded Warrants”) and (ii) accompanying warrants to purchase up to an aggregate of 17,333,332 shares of its Common Stock (the “Common Warrants”) at a combined offering price of $1.80 per share of Common Stock and associated Common Warrant, or $1.799 per Pre-Funded Warrant and associated Common Warrant, resulting in gross proceeds of approximately $15.6 million.”
TENAX THERAPEUTICS, INC.: Certificate of Amendment filed to effect reverse stock split of common stock at 1-for-20 ratio (effective 2023-01-04).
“Tenax Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Certificate of Incorporation, as amended (the “Certificate of Amendment”) with the Secretary of State of Delaware for the purpose of effecting a reverse stock split (the “Reverse Stock Split”) of the outstanding shares of the Company’s common stock at a ratio of one share for every 20 shares outstanding”
Keith Maher resigned as Director at TENAX THERAPEUTICS, INC..
“On June 10, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capital, LLC, the investment manager to Armistice Capital Master Fund Ltd. (the “Master Fund”), notified the Board of Directors (the “Board”) of Tenax Therapeutics, Inc. (the “Company”) that they have resigned from the Board.”
Steven Boyd resigned as Director at TENAX THERAPEUTICS, INC..
“On June 10, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capital, LLC, the investment manager to Armistice Capital Master Fund Ltd. (the “Master Fund”), notified the Board of Directors (the “Board”) of Tenax Therapeutics, Inc. (the “Company”) that they have resigned from the Board.”
Robyn M. Hunter was appointed as Member of the Board at TENAX THERAPEUTICS, INC..
“On January 26, 2022, the Board of Directors (the “Board”) of Tenax Therapeutics, Inc. (the “Company”) appointed Robyn M. Hunter as a member of the Board, effective January 28, 2022, to serve until the Company’s 2022 annual meeting of stockholders or until her successor is duly elected and qualified.”
Eliot M. Lurier was appointed as Interim Chief Financial Officer at TENAX THERAPEUTICS, INC..
“the Company has entered into a consulting agreement with Danforth Advisors, LLC (“Danforth”), dated October 14, 2021, providing for the engagement of Eliot M. Lurier, a consultant with Danforth, as Interim Chief Financial Officer of the Company”
Christopher T. Giordano changed role as President at TENAX THERAPEUTICS, INC..
“the Company’s current Chief Executive Officer and principal executive officer, Christopher T. Giordano, will assume the additional position of President of the Company.”
Michael B. Jebsen departed as Chief Financial Officer at TENAX THERAPEUTICS, INC..
“Michael B. Jebsen, the Company's President and Chief Financial Officer, agreed that Mr. Jebsen would separate from the Company effective October 29, 2021”
Michael B. Jebsen departed as President at TENAX THERAPEUTICS, INC..
“Michael B. Jebsen, the Company's President and Chief Financial Officer, agreed that Mr. Jebsen would separate from the Company effective October 29, 2021”
James Mitchum resigned as Director at TENAX THERAPEUTICS, INC..
“On September 8, 2021, James Mitchum notified the Company that he is voluntarily resigning from the Board and its Audit and Compliance Committee and Compensation Committee, effective immediately.”
Christopher T. Giordano was appointed as Chief Executive Officer at TENAX THERAPEUTICS, INC..
“On July 6, 2021, the Board appointed Christopher T. Giordano as the Company’s Chief Executive Officer and a member of its Board of Directors, effective July 14, 2021.”
Anthony A. DiTonno retired as Chief Executive Officer at TENAX THERAPEUTICS, INC..
“On July 13, 2021, Anthony A. DiTonno will retire as the Chief Executive Officer of the Company and as a member of the Company’s Board of Directors (the “Board”) effective as of July 13, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.